Select publications

Antonia SJ et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy in advanced non-small cell lung cancer (NSCLC): Metastatic non-small cell lung cancer. Chicago Multidisciplinary Symposium in Thoracic Oncology 2014;Abstract 3.

Balmanoukian AS et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer: Novel therapies/experimental therapies. Chicago Multidisciplinary Symposium in Thoracic Oncology 2014;Abstract 2.

Brahmer JR et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. Proc ASCO 2014;Abstract 8021.

Drilon A et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in “driver-negative” lung adenocarcinomas. Clin Cancer Res 2015;[Epub ahead of print]. Abstract

Gadgeel SM et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15(10):1119-28. Abstract

Garon EB et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384(9944):665-73. Abstract

Gregorc V et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): A biomarker-stratified, randomised phase 3 trial. Lancet Oncol 2014;15(7):713-21. Abstract

Herbst RS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515(7528):563-7. Abstract

Janjigian YY et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov 2014;4(9):1036-45. Abstract

Jänne PA et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. Proc ASCO 2014;Abstract 8009.

Kelly K et al. A randomized, double-blind Phase 3 trial of adjuvant erlotinib vs placebo following complete tumor resection with or without adjuvant chemotherapy in patients with Stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer: RADIANT results. Proc ASCO 2014;Abstract 7501.

Kim DW et al. Ceritinib in advanced anaplastic lymphoma kinase rearranged non-small cell lung cancer: Results of the ASCEND-1 trial. Proc ASCO 2014;Abstract 8003.

Leighl NB et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guideline. J Clin Oncol 2014;32(32):3673-9. Abstract

Mok TS et al. Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer after progression on first-line gefitinib: The phase III, randomized IMPRESS study. Proc ESMO 2014;Abstract LBA2_PR.

Planchard D et al. Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer: A multicenter, open-label, phase II trial (BRF113928). Proc ESMO 2014;Abstract LBA38_PR.

Ramalingam SS et al. Phase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer: Metastatic non-small cell lung cancer. Chicago Multidisciplinary Symposium in Thoracic Oncology 2014;Abstract LB2.

Rizvi N et al. A Phase 2, non-comparative, open-label, multicenter, international study of MEDI4736 in patients with locally advanced or metastatic PD-L1-positive NSCLC (Stage IIIB-IV) who have received ≥ 2 prior systemic treatment regimens, including a platinum-based chemotherapy (ATLANTIC). Proc ESMO 2014;Abstract 1335TiP.

Rizvi NA et al. Clinical trials of MPDL3280A (anti-PDL1) in patients with non-small cell lung cancer. Proc ASCO 2014;Abstract TPS8123.

Sequist LV et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). Proc ASCO 2014;Abstract 8010.

Seto T et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014;15(11):1236-44. Abstract

Shepherd FA et al. Adjuvant erlotinib versus placebo in non-small cell lung cancer patients with tumors carrying EGFR-sensitizing mutations from the RADIANT trial. Proc ASCO 2014;Abstract 7513.

Thatcher N et al. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11 F8/LY3012211) versus GC alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. Proc ASCO 2014;Abstract 8008.

Yang JC et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16(2):141-51. Abstract